

ASX & MEDIA RELEASE

Successful Completion of Institutional Entitlement Offer

Not for release or distribution in the United States

25 February 2022, Melbourne

Highlights

- Approximately \$43 million raised through the Institutional Entitlement Offer at \$3.44 per New Share
- Well supported by existing eligible institutional shareholders, with take up of approximately 91% under the Institutional Entitlement Offer
- Retail Entitlement Offer to raise approximately \$47 million
- Retail Entitlement Offer opens on Tuesday, 1 March 2022 and closes at 5.00pm (Melbourne time) on Monday, 14 March 2022
- Proceeds of the Entitlement Offer will be used to fund the acquisition of Peloton Radiology, pay associated transaction costs, as well as provide additional balance sheet flexibility to support investment in identified bolt-on M&A opportunities that are aligned to IDX's strategy

Completion of Institutional Entitlement Offer

Integral Diagnostics Limited (ASX:IDX) is pleased to announce the successful completion of the institutional component (**Institutional Entitlement Offer**) of its 1 for 7.75 pro-rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) of new shares (**New Shares**), which was announced on Wednesday, 23 February 2022. The Institutional Entitlement Offer raised approximately \$43 million through the issue of approximately 12.5 million New Shares at \$3.44 per New Share (**Offer Price**) and was well supported by existing eligible institutional shareholders, who took up approximately 91% of their entitlements.

The institutional shortfall was significantly oversubscribed by both existing eligible institutional shareholders and new institutional investors.

Each New Share issued under the Institutional Entitlement Offer will rank equally with existing IDX shares on issue but will be issued after the dividend record date and will not be eligible for the interim 1H FY22 dividend of 4 cents per share.

New Shares under the Institutional Entitlement Offer are expected to be allotted on Monday, 7 March 2022 and trading on a normal settlement basis is expected to commence on the ASX on the same day.

IDX expects its trading halt to be lifted and IDX shares to recommence trading from market open today (Friday, 25 February 2022).

Dr Ian Kadish, Managing Director and CEO of Integral Diagnostics, commented:

"We greatly appreciate the support we have received from existing shareholders and new investors, and look forward to continuing to deliver on our business strategy, as well as welcoming Peloton Radiology into the Integral Diagnostics group following completion of the acquisition."

Retail Entitlement Offer

Eligible retail shareholders will be invited to participate in the retail component of the Entitlement Offer (**Retail Entitlement Offer**) at the same Offer Price and offer ratio as under the Institutional Entitlement Offer. The Retail Entitlement Offer is expected to raise approximately \$47 million.

The Retail Entitlement Offer is expected to open on Tuesday, 1 March 2022 and close at 5.00pm (Melbourne time) on Monday, 14 March 2022 (**Retail Offer Period**).

Further details about the Retail Entitlement Offer will be set out in an information booklet (**Retail Offer Booklet**), which IDX will lodge with the ASX on Tuesday, 1 March 2022. The Retail Offer Booklet and accompanying Entitlement and Acceptance Form are expected to be made available to eligible retail shareholders on the same day.

Eligible retail shareholders with registered addresses in Australia or New Zealand and who hold IDX shares on the record date of 7.00pm (Melbourne time) on Friday, 25 February 2022 will have the opportunity to apply for New Shares at the Offer Price under the Retail Entitlement Offer. In addition, eligible retail shareholders who take up all of their entitlement may also apply for additional New Shares in excess of their entitlement, up to an additional 50% of their entitlement. Eligible retail shareholders are not assured of being allocated any New Shares in excess of their entitlement, which will be allocated in accordance with the allocation policy outlined in the Retail Offer Booklet.

Further details of the Retail Entitlement Offer were set out in IDX's announcement on Wednesday, 23 February 2022 and the terms and conditions will be fully set out in the Retail Offer Booklet. Eligible retail shareholders should carefully read the Retail Offer Booklet and accompanying Entitlement and Acceptance Form.

You should seek appropriate professional advice before making any investment decision. If you have any questions about the Retail Entitlement Offer, please contact the IDX Offer Information Line on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30am and 5.00pm (Melbourne time), Monday to Friday during the Retail Offer Period.

For further details contact

Integral Diagnostics

Kirsty Lally

M: +61 402 094 569

Authorised for lodgement by the Managing Director and CEO, Dr Ian Kadish

About IDX:

Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. The Company provides state of the art diagnostic services to patients and their referrers at 71 radiology clinics, including 29 comprehensive sites. IDX employs some of Australasia's leading radiologists and nuclear medicine specialists in a unique medical leadership model that ensures quality patient care, service and access. Good medicine is good business. For more information, please visit www.integraldiagnostics.com.au/.

Important Notices

FORWARD-LOOKING STATEMENTS

This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance, including the outcome of the acquisition of Peloton Radiology and performance and any synergies of the combined businesses following the acquisition of Peloton Radiology and the outcome of the Entitlement Offer are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of IDX, its directors and management, including any further impacts of COVID-19 on IDX’s continued trading and operations. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the outbreak of COVID-19. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of IDX’s business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of IDX, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to IDX as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of IDX, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

This announcement is not financial product advice and has not taken into account your objectives, financial situation or needs. This announcement has been prepared for release in Australia. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any jurisdiction in which such an offer would be illegal. The New Shares have not been, nor will be, registered under the U.S. Securities Act of 1933 (the Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, to any person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws.